Atypical Hemolytic Uremic Syndrome market Forecast. DelveInsight's Atypical Hemolytic Uremic Syndrome Market report offers an in-depth understanding of the ...

Eculizumab biosimilar Elizaria demonstrates long-term safety and efficacy comparable with the reference product Soliris in ...

In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...

AstraZeneca Pharma India received a Central Drugs Standard Control Organisation (CDSCO) permission to import, sale or distribute ‘Eculizumab’ concentrate solution for infusion 300 mg (10mg/ml).

Indian Bank, TVS Motor, Bajaj Healthcare, Ravindra Energy, BPCL, AIA Engineering, IREDA, AstraZeneca, MobiKwik, HFCL, PFC, ...

AstraZeneca share rose after it that the company has secured permission to import pharmaceutical formulations of new drug for sale or for distribution in Form CT-20 from CDSCO ...

According to the exchange filing, regulatory authority Central Drugs Standard Control Organisation has allowed it to import pharmaceutical formulations of its drug Eculizumab for sale or for ...

AstraZeneca Pharma India has received approval from the Central Drugs Standard Control Organisation (CDSCO) to import pharmaceutical formulations of eculizumab concentrate, marketed as Soliris. The ...

Eculizumab effectively reduced MG-ADL scores and corticosteroid use in thymoma-associated myasthenia gravis patients by week 12. The monoclonal antibody targets complement protein C5, preventing ...

In the U.S., EPYSQLI (eculizumab-aagh) was approved by the U.S. Food and Drug Administration (FDA) as a biosimilar to Soliris ® (eculizumab) in July 2024 for the treatment of patients with paroxysmal ...